Vera Therapeutics VERA Gain (loss) on available-for-sale debt securities
Gain (loss) on available-for-sale debt securities at other companies
Other financials
Where this comes from
Reported directly by Vera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss.
The official record: Vera Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Vera Therapeutics's gain (loss) on available-for-sale debt securities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Vera Therapeutics's gain (loss) on available-for-sale debt securities?
- Vera Therapeutics (VERA) reported gain (loss) on available-for-sale debt securities of -$942K in Q1 2026.
- How has Vera Therapeutics's gain (loss) on available-for-sale debt securities changed year-over-year?
- Vera Therapeutics's gain (loss) on available-for-sale debt securities decreased by 460.9% year-over-year, from $261K to -$942K.
- What does gain (loss) on available-for-sale debt securities mean?
- This metric represents the change in the fair value of debt securities classified as available-for-sale that has not yet been realized through a sale. It reflects unrealized fluctuations in the market value of the company's investment portfolio due to changes in interest rates or credit spreads. Monitoring this figure helps investors understand the volatility and potential impact of market conditions on the company's non-operating financial position.